Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria – a post-hoc analysis of the PRIORITY randomized clinical trial
Author:
Curovic Viktor1, Tofte Nete1, Lindhardt Morten1, Adamova Katarina2, Bakker Stephan J.L.3, Beige Joachim4, Beulens Joline W.J.5, Birkenfeld Andreas L.6, Currie Gemma7, Delles Christian7, Dimos Ingo8, Francová Lidmila9, Frimodt-Møller Marie1, Girman Peter10, Göke Rüdiger11, Hansen Tine W.1, Havrdova Tereza10, Kooy Adriaan12, Laverman Gozewijnw D.13, Mischak Harald14, Navis Gerjan3, Nijpels Giel15, Noutsou Marina16, Ortiz Alberto17, Parvanova Aneliya18, Persson Frederik1, Petrie John R.7, Ruggenenti Piero L.18, Rutters Femke5, Rychlík Ivan9, Siwy Justyna14, Spasovski Goce19, Speeckaert Marijn20, Trillini Matias18, Zürbig Petra14, Leyen Heiko von der21, Rossing Peter1
Affiliation:
1. Steno Diabetes Center Copenhagen 2. University Clinic of Endocrinology 3. University of Groningen 4. Hospital St Georg 5. Amsterdam UMC, location Vrije Universiteit Amsterdam 6. University Hospital Tübingen 7. University of Glasgow 8. Diabetespraxis 9. Charles University 10. Diabetes Center Institute for Clinical and Experimental Medicine 11. Diabetologen Hessen 12. Bethesda Diabetes Research Center 13. Ziekenhuisgroep Twente Hospital 14. Mosaiques Diagnostics GmbH 15. Department of General Practice and Elderly Care 16. National and Kapodistrian University of Athens, Hippokratio General Hospital 17. Instituto de Investigacion Sanitaria de la Fundacion Jiménez Díaz UAM 18. Istituto di Ricerche Farmacologiche Mario Negri IRCCS 19. Cyril and Methodius University in Skopje 20. Ghent University Hospital 21. Orgenesis Germany GmbH
Abstract
Abstract
Background
Diabetic retinopathy (DR) is a microvascular complication of diabetes highly associated to cardiovascular disease and diabetic kidney disease. However, these associations are not thoroughly investigated at an early type 2 diabetes disease stage. This study therefore evaluated the association between baseline DR status and development of cardiovascular events (CVEs), microalbuminuria, and kidney function decline and in persons with type 2 diabetes and normal urinary albumin excretion.
Methods
Post-hoc analysis of the PRIORITY study including 1758 persons with type 2 diabetes and normoalbuminuria followed for a median of 2.5 (IQR: 2.0–3.0) years. The study was originally designed to investigate a urinary proteomic risk classifier predictor of microalbuminuria development. DR at baseline was defined as non-proliferative and proliferative abnormalities, macular oedema, or history of laser treatment. Cox models were fitted to investigate the association of DR status with development of 1) a CVE composite defined as non-fatal myocardial infarction, stroke, coronary artery bypass graft, percutaneous coronary intervention, hospitalization for heart failure, or all-cause mortality; 2) persistent microalbuminuria (urinary albumin-creatinine ratio > 30mg/g); and 3) chronic kidney disease (CKD) G3 (eGFR < 60 mL/min/1.73m2). Models were adjusted for relevant risk factors.
Results
At baseline, 304 (17.3%) had DR. Compared to persons without DR, they were older (mean ± SD: 62.7 ± 7.7 vs 61.4 ± 8.3 years, p = 0.019), had longer diabetes duration (17.9 ± 8.4 vs. 10.6 ± 7.0 years, p < 0.001), and higher HbA1c (62 ± 13 vs. 56 ± 12 mmol/mol, p < 0.001). The adjusted hazard ratios of DR at baseline for development of CVE (n = 64), microalbuminuria (n = 197), and CKD (n = 166) were: 2.61 (95%CI: 1.44, 4.72), 1.50 (95%CI: 1.07, 2.11), and 0.87 (95%CI: 0.56, 1.34), and, compared to without DR. Baseline levels of the urinary proteomics classifier did not influence the results.
Conclusions
Presence of DR in normoalbuminuric type 2 diabetes was associated with an increased risk of developing CVE and microalbuminuria, but not with kidney function decline.
Publisher
Research Square Platform LLC
Reference23 articles.
1. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association;Young-Hyman D;Diabetes Care,2016 2. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021;Association AD;Diabetes Care,2020 3. Diabetic Retinopathy: A Position Statement by the American Diabetes Association;Solomon SD;Diabetes Care,2017 4. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes care. 2014;37(10):2864-83. 5. American Diabetes A 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2020;44(Supplement_1):S125-S50.
|
|